Get the Stockscreener App
1.00
0.76%
0.0075
After Hours:
1.01
0.01
+1.00%
Metavia Inc stock is traded at $1.00, with a volume of 51,706.
It is up +0.76% in the last 24 hours and down -2.91% over the past month.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
See More
Previous Close:
$0.9925
Open:
$0.99
24h Volume:
51,706
Relative Volume:
0.03
Market Cap:
$24.20M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+3.43%
1M Performance:
-2.91%
6M Performance:
+28.39%
1Y Performance:
+0.00%
1-Day Range:
$0.979
$1.0098
1-Week Range:
$0.951
$1.01
52-Week Range:
$0.5555
$2.75
Metavia Inc Stock (MTVA) Company Profile
Name
Metavia Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE
Compare MTVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
1.00 | 24.02M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
Metavia Inc Stock (MTVA) Latest News
What’s next for MetaVia Inc. stock price2025 Major Catalysts & Free Growth Oriented Trading Recommendations - newser.com
MetaVia Inc. stock prediction for this weekJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
MetaVia Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Real time breakdown of MetaVia Inc. stock performanceJuly 2025 Selloffs & Detailed Earnings Play Strategies - newser.com
Why MetaVia Inc. stock could outperform in 2025July 2025 Chart Watch & Low Drawdown Momentum Trade Ideas - newser.com
Is it too late to sell MetaVia Inc.Market Growth Review & Free AI Powered Buy and Sell Recommendations - newser.com
How to manage a losing position in MetaVia Inc.July 2025 Trends & AI Powered Trade Plan Recommendations - newser.com
Sector ETF performance correlation with MetaVia Inc.Trade Ideas & Daily Oversold Bounce Ideas - newser.com
How MetaVia Inc. stock reacts to bond yields2025 Trading Volume Trends & Real-Time Volume Spike Alerts - newser.com
Ranking MetaVia Inc. among high performing stocks via toolsJuly 2025 Catalysts & Low Risk Growth Stock Ideas - newser.com
How to build a dashboard for MetaVia Inc. stockTrade Entry Summary & Free Daily Entry Point Trade Alerts - newser.com
Metavia Inc. Advances Obesity Treatment with New Clinical Study - TipRanks
MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting - Lelezard
MetaVia (Nasdaq: MTVA) to present vanoglipel (DA-1241) MASH poster at AASLD Nov 10 - Stock Titan
Metavia Inc Stock (MTVA) Financials Data
There is no financial data for Metavia Inc (MTVA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):